Iron Chelators for Thalassaemia
Open Access
- 1 June 1998
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 101 (3) , 399-406
- https://doi.org/10.1046/j.1365-2141.1998.00726.x
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Evaluation of a new method of administration of the iron chelating agent deferoxamineThe Journal of Pediatrics, 1997
- Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamineEuropean Journal of Pediatrics, 1996
- Dynamics of the cytosolic chelatable iron pool of K562 cellsFEBS Letters, 1996
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Design, Properties, and Effective Use of the Oral Chelator L1 and OtherAnnals of the New York Academy of Sciences, 1990
- L1 (1,2‐dimethyl‐3‐hydroxypyrid‐4‐one) for oral iron chelation in patients with beta‐thalassaemia majorBritish Journal of Haematology, 1990
- Iron-Chelating TherapyCRC Critical Reviews in Clinical Laboratory Sciences, 1988
- Yersinia Sepsis in Patients with Iron Overload Treated with DeferoxamineNew England Journal of Medicine, 1986
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986
- Magnetic-Susceptibility Measurement of Human Iron StoresNew England Journal of Medicine, 1982